Browse Articles
Discover research articles across all indexed journals
Characteristics and outcomes of patients with early-onset versus average-onset small bowel neuroendocrine tumors.
670 Background: The global incidence of early-onset gastrointestinal cancers (GI) is increasing. Although patients with more common early-onset GI cancers, e.g. colorectal cancer, often present with more advanced disease and experience relatively worse outcomes; the characteristics and treatment outcomes for less common early-onset small bowel neuroendocrine tumors (SBNETs) have yet to be explored. Methods: We used the Surveillance, Epidemiology, and End Results (SEER) database to identify patients with SBNETs (2004-2021), using ICD-0-3 SEER histology codes (8240/3, 8241/3, 8243/3, 8244/3, 8249/3, 8246/3). Patients with poorly differentiated histology were excluded. We used the chi-square test to compare categorical variables between early-onset SBNETs (EO-SBNETs, aged 30-49 years) and average-onset SBNETs (AO-SBNETs, aged ≥ 50 years) patients. Overall survival was estimated using the Kaplan-Meier method followed by application of the log-rank test to assess for differences in survival. A multivariable Cox regression analysis included early onset of disease, sex, race/ethnicity, marital status, urban/rural residence, prior treatments, and disease extent as covariates. All tests were conducted with a significance threshold of p < 0.05 using RStudio. Results: A total of 3,713 patients were included, of which, 925 (25%) were EO-SBNETs. Compared to AO-SBNETs, EO-SBNETs patients were more likely to be females (51.1% vs 46.7%, p=0.02), non-Hispanic Black (20.8% vs 17.6%, p=0.04), Hispanic (13.6% vs 8.8%, p<0.0001) and less likely to be non-Hispanic White 60.8% vs 69.9%, p<0.0001). There were no differences in stage at diagnosis between the EO-SBNETs and AO-SBNETs, i.e,, localized disease (33.5% vs 31.0%, p=0.15), regional spread (41.9% vs 42.8%, p=0.64) and distant metastatic disease (20.9% vs 21.9%, p=0.50). There were no differences in receipt of surgical resection (90.5% vs 89.1%, p=0.25) or chemotherapy (5% vs 6.3%, p=0.15) comparing EO-SBNETs and AO-SBNETs respectively. In a multivariate cox regression analysis, early onset was associated with a significantly better overall survival (HR=0.49, 95% CI 0.41-0.59, p<0.0001). Conclusions: With this first of its kind analysis, significantly superior overall outcomes among EO-SBNETs despite no differences in stage and receipt of surgery establishes age at diagnosis as a significant prognostic factor for SBNETs. Further studies investigating the role of factors such as differences in tumor biology and patient preferences in receipt of other therapies besides surgery are needed.
Longitudinal and Noninvasive Intracellular Recordings of Spontaneous Electrophysiological Activity in Rat Primary Neurons on Planar MEA Electrodes
Abstract Presently, the in vitro recording of intracellular neuronal signals on microelectrode arrays (MEAs) requires complex 3D nanostructures or invasive and approaches such as electroporation. Here, it is shown that laser poration enables intracellular coupling on planar electrodes without damaging neurons or altering their spontaneous electrophysiological activity, allowing the process to be repeated multiple times on the same cells. This capability distinguishes laser‐based neuron poration from more invasive methods like electroporation, which typically serve as endpoint measurement for cells. It is demonstrated that planar MEA electrodes, when combined with laser cell optoporation and live cell staining, can record spontaneous intracellular signaling from primary neurons in vitro. This approach allows for the detection of attenuated signals resembling positive monophasic intracellular action potentials. Recordings after laser optoporation also reveal subthreshold signals such as post‐synaptic potentials that are essential for assessing neuronal network plasticity and connectivity. Moreover, the noninvasiveness of the process enables repeated intracellular recordings over multiple days from the same cells.
Development and validation of machine learning model for mortality after curative gastrectomy for gastric cancer.
386 Background: The risk for postoperative complications can significantly impact perioperative planning. The aim of this study is to develop and validate a model based on various machine learning techniques to predict postoperative mortality (PM) after curative radical gastrectomy for gastric cancer. Methods: Data from a nationwide survey led by the Korean Gastric Cancer Association was used for the development set, which included 12,722 patients who underwent gastrectomy in 2019 across 68 institutions in South Korea. The validation set comprised 4,887 patients from 8 institutions between 2009 and 2017. PM was defined as all-cause death within 30 days after surgery or in-hospital death beyond 30 days. Five machine learning models (CatBoost, Gradient Boosting, Light GBM, Random Forest, XGBoost) were evaluated using perioperative clinical characteristics. Model performance was assessed using the area under the receiver operation characteristic curve (AUROC) with 5-fold cross-validation. Results: The PM rates were 0.83% and 1.04% in the development and validation set, respectively. In the development set, the Random Forest model demonstrated the highest discrimination capacity with an AUROC of 0.772, followed by Gradient Boosting at 0.767, CatBoost at 0.742, XGBoost at 0.732, and LightGBM at 0.717. However, in the validation set, CaBoost showed the highest AUROC at 0.747, while the AUROC for Random Forest decreased to 0.688. Conclusions: The CatBoost model demonstrated robust and consistent performance in predicting PM risk across both development and validation datasets. To further enhance the performance of the model and ensure stable clinical application, future research should focus on developing methods for quantitative measurement of perioperative factors such as surgical techniques.
Leveraging large-scale PDO-based assays to optimize antibody-drug conjugate efficacy in CRC.
261 Background: Clinical trials are one of the major barriers in contemporary drug development. Functional assays based on patient-derived organoids (PDO) are a promising new tool for derisking clinical development of new therapies, but their use has been limited due to small cohort sizes and the absence of systematic validation studies. Using the largest cohort of matched PDOs, longitudinal clinical data, transcriptomic and WES data in CRC, we explore the use of large PDOs collections to characterize ADC efficacy and affinity through systematic mapping of the relationship between target antigen affinity and payload efficacy. Methods: We have assembled a collection of 85 PDOs from colorectal cancer (CRC), generated from primary tumour samples and metastatic biopsies. Patients ranged from 32 to 89 years old and had experienced an average of 1.54 lines of treatment prior to the PDO-generating tissue sampling. Using gene expression levels of well known target antigens such as CEACAM5, ERBB2, MSLN and TROP2 as a proxy for protein concentration, we explore the relationship between the target antigen affinity and the efficacy of a subset of common payloads including topoisomerase and microtubule inhibitors. This allows us to identify the relationship between two of the three main vectors of ADC efficacy in CRC. Results: We show that topoismerase inhibitor and microtubule inhibitor efficacy relates to the RNA expression level of multiple target antigens commonly used in active clinical trials in CRC. These data match the target antigen and payload couples currently under development or approved in the clinic. We are developing a tool to optimize clinical trial design. This approach will allow us to match patients more accurately with the appropriate payload, ensuring a higher likelihood of response. Conclusions: We report that large-scale PDO-based assays can be a useful tool to anticipate clinical readouts. This work suggests that well-characterized PDO collections could also help redefine patient populations, increasing the likelihood of identifying those more likely to respond to a given ADC, and thus improving the success rates of clinical studies for new treatments in CRC.
Exploring predictive factors for detecting KRAS mutations in pancreatic cancer using liquid biopsy.
782 Background: Liquid biopsy offers an alternative to tissue specimens for comprehensive genetic profiling. However, circulating tumor DNA is sometimes insufficient to detect genomic alterations in pancreatic cancer (PC). The detection rate of KRAS mutations was reportedly increased in PC with liver metastasis. In contrast, the predictive value of CA19-9 levels, the timing of liquid biopsy, or the type of liquid biopsy for detecting KRAS mutations remains unclear. We investigated whether these factors could be predictive of detecting KRAS mutations in PC. Methods: From September 2021 to August 2024, we retrospectively reviewed patients with PC who underwent liquid biopsy. Results: A total of 106 patients were enrolled (median age: 64 years, male: 66). Patient characteristics were as follows: tumor status: locally advanced: 10, metastatic: 90, recurrence: 6; metastatic site: liver: 51, lung: 26, lymph nodes: 20, peritoneum: 38, others: 7; number of metastatic sites: 1: 63, 2: 25, ≥3: 8; treatment line at liquid biopsy: 1: 21, 2: 77, 3:8; median CA19-9 level: 1053.4 U/mL; type of liquid biopsy: FoundationOne Liquid CDx (FL): 75 or Guardant360 (G): 31. The overall rate of KRAS mutations was 47%, with a median variant allele frequency of 0.83 [range:0.1-71.0]. The patterns of KRAS mutations were as follows: G12D: 23, G12V: 18, G12R: 4, and others: 14. The detection rate of KRAS mutations varied by the follows factors: metastatic site: liver: 65%, other organs: 44%; number of metastatic sites: ≥2: 47%, <2: 48%; CA19-9 level: ≥2,000 U/mL: 68%, <2,000: 38%; timing of liquid biopsy: 1st line: 42%, ≥2nd line: 67%; types of liquid biopsy: FL: 49%, G: 42%. In multivariate analysis, liver metastasis and CA19-9 level ≥2,000 U/mL were identified as independent factors associated with improved detection of KRAS mutations. In PC with these two factors, the detection rate of KRAS mutation increased to 76%. Conclusions: Our findings indicate that liver metastasis and CA19-9 levels above 2,000 U/mL are predictive factors for detecting KRAS mutations in PC through liquid biopsy.
Optical Activity of Chiral Excitons
AbstractRecent activity in the area of chiroptical phenomena has been focused on the connection between structural asymmetry, electron spin configuration and light/matter interactions in chiral semiconductors. In these systems, spin‐splitting phenomena emerge due to inversion symmetry breaking and the presence of extended electronic states, yet the connection to chiroptical phenomena is lacking. Here, we develop an analytical effective mass model of chiral excitons, parameterized by density functional theory. The model accounts for parity mixing of the band edge Bloch functions resulting from polar distortions, resulting in allowed magnetic dipole transitions. Through the study of a prototypical chiral 2D hybrid perovskite semiconductor, we show that circular dichroism of the chiral exciton and its interband continuum emerges from spin‐splitting via cross‐coupling of Rashba‐like and chiral/helical spin‐texture components. To demonstrate the generality of our approach, and as a counterpoint, we apply our model to describe chiroptical properties of three‐dimensionally confined excitons in perovskite nanocrystals that occur without chiral lattice distortions.
QL1203 vs placebo plus mFOLFOX6 as first-line therapy in RAS wild-type, metastatic colorectal cancer (mCRC): Interim analysis (IA) of a multicenter, randomized, double-blinded, parallel, phase 3 trial.
190 Background: Panitumumab plus FOLFOX or FOLFIRI has been approved as the first-line therapy for RAS wild-type mCRC. QL1203 is a panitumumab biosimilar showing similarity to the originator panitumumab (Vectibix, Amgen) in preclinical studies and phase 1 clinical pharmacokinetic study. Here we present results from interim analysis of a phase 3 trial (NCT04233151) investigating QL1203 vs placebo plus mFOLFOX6 as first-line therapy in Chinese patients (pts) with RAS wild-type mCRC. Methods: Pts with treatment-naïve, RAS and BRAF wild-type, mCRC unsuitable for radical resection and local therapy were enrolled and randomly assigned (2:1) to receive QL1203 (6 mg/kg) plus mFOLFOX6 once every 2 weeks (Q2W) or placebo plus mFOLFOX6 Q2W, stratified by primary tumor site, liver metastases, and previous neoadjuvant/adjuvant therapy. The primary endpoint was PFS assessed by a Blinded Independ Review Committee (BICR) per RECIST v1.1. Key secondary endpoints include PFS by investigator (INV), OS, ORR, DoR, and safety. This planned IA was conducted at 338 (81.25%) of 416 PFS events occurred. Results: From Jan 8, 2020 to Jun 12, 2023, 641 pts were randomized (QL1203/placebo, n=426/215). 551 (86.0%) pts had left-sided tumors (QL1203/placebo, 85.9%/86.0%). 433 (67.6%) pts had liver metastases (QL1203/placebo, 68.1%/66.5%). As of data cutoff of this IA (Mar 22, 2024), median follow-up was 23.8 months. Median PFS by BIRC was 11.20 months for QL1203 and 8.34 months for placebo (hazard ratio [HR], 0.61 [97.42% confidence interval [CI], 0.47-0.79]; stratified one-sided log-rank p<0.0001). Other efficacy results are presented (Table). Incidence of grade≥ 3 adverse events (AEs) related to study drug was 59.9% for QL1203 and 32.9% for placebo. The most common grade≥3 AE related to QL1203 was neutrophil count decreased (20.3%). Conclusions: QL1203 demonstrated significantly improved PFS versus placebo and higher ORR. Clinical trial information: NCT04233151 . QL1203 (n=426) Placebo (n=215) PFS by BIRC mPFS, months (95% CI) 11.20 (9.89-13.11) 8.34 (7.26-8.54) HR (97.42% CI) 0.61 (0.47-0.79) PFS by INV mPFS, months (95% CI) 10.91 (9.69-11.30) 8.41 (7.39-9.07) HR (95% CI) 0.74 (0.60-0.91) mOS, months (95% CI) 27.66 (24.74-32.79) 24.54 (20.17-27.79) HR (95% CI) 0.82 (0.64-1.06) ORR by BIRC, n (%) 68.31% 47.91% 95% CI 63.66-72.70 41.07-54.81 ORR by INV, n (%) 64.08% 49.30% 95% CI 59.33-68.65 42.44-56.19
A multicenter prospective study to evaluate the efficacy of resection for initially unresectable hepatocellular carcinoma after atezolizumab combined with bevacizumab (the RACB study): Short-term outcomes.
521 Background: The IMbrave150 study showed that atezolizumab plus bevacizumab (atezo+bev) is superior to sorafenib in progression-free survival and overall survival, making it the recommended first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). The RACB study was scheduled to evaluate the efficacy of atezo+bev in achieving conversion surgery for initially unresectable HCC. This time, we report the short-term outcomes of the RACB study. Methods: This prospective, single-arm, multicenter Phase II trial evaluates atezo+bev to achieve conversion surgery in patients with technically or oncologically unresectable HCC. Eligible patients had unresectable HCC without prior systemic chemotherapy and at least one target lesion based on RECIST ver1.1. Patients received atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) every three weeks. If resectable on radiological assessment at 12 weeks, atezolizumab monotherapy was given followed by surgery. The primary endpoint was the progression-free survival. The secondary endpoints included the overall response rate, overall survival, resection rate, curative resection rate, on-protocol resection rate, and ICG retention rate at 15 min after atezo+bev therapy. The study is registered with the Japan Registry of Clinical Trials (jRCTs051210148). Results: Between March 2022 and March 2024, 55 patients from 17 centers were enrolled. Four patients were excluded due to ineligible lesions or other reasons. A total of 50 patients were included in the efficacy evaluation set. Macrovascular invasion and extrahepatic metastases were observed in 38 (76.0%) and 6 patients (12.0%), respectively. Two patients (4.0%) had metachronous extrahepatic metastases without intrahepatic tumors. The complete and partial response rates were 0% and 13% based on RECIST, and 2.2% and 26.1% based on mRECIST. The overall resection rate was 48%, corresponding to 24 cases. R0, R1, and R2 resections were performed in 21 (87.5%), 1 (4.2%), and 2 (8.3%) patients, respectively. Complications ≥Grade III according to the Clavien-Dindo classification included 3 bile leakages, 2 infections, 1 anastomotic leakage, and 1 hemoptysis. There were no surgery-related deaths. Of the 51 patients included in the safety analysis set, adverse events occurred in 34 cases (66.7%), with 16 Grade 3 or higher instances with one Grade 4 upper gastrointestinal bleeding, 1 Grade 4 encephalopathy, and 1 unexpected death after 1 cycle of atezo+bev. Conclusions: The RACB study's short-term outcomes demonstrated the feasibility of conversion surgery after atezo+bev in patients with initially unresectable HCC. The response rate of atezo+bev, as measured by mRECIST, was similar to IMbrave150, with a 48% resection rate, though careful monitoring of severe adverse events is essential. Clinical trial information: 051210148.
Clinical-pathologic characteristics in young patients with metastatic colorectal cancer: Experience from a specialized cancer institute in Peru.
279 Background: Colorectal cancer (CRC) represents the third cause of malignant neoplasm in the world and the second in terms of mortality. CRC is a major cause of cancer-related morbidity and mortality in Peru. Diagnosis at younger ages represents a challenge. In this study, we evaluated prognostic factors in patients who were metastatic at diagnosis or progressed to metastatic disease during follow-up. Methods: A descriptive cross-sectional study, between 2013 and 2022, 66 patients under 40 years old and stage IV at diagnosis were analyzed. Parameters evaluated were age, gender, comorbidity, performance status and stage of the disease at the diagnosis, localization, surgery undergone, systemic treatment regimen, response to first-line treatment, incidence of K-RAS, sites and number of metastases, expression of tumor predictors (CEA levels), and survival times. A multivariate analysis was conducted with factors that were considered statistically significant in the univariate analysis. Results: Median age was 35 years [29.25-37] and the female/male ratio was 34/32. From 66 patients at stage IV disease, 30 patients (45.5%) were right-side, 36 (54.5%) were left-side colon cancer. At the end of follow-up, 51 patients had died, and 15 survived. Overall survival (OS) was significantly better in patients older than 35 years old (p<0,05), those who underwent primary tumor surgery (p<0,001), negative perineural invasion (p<0.0045). The treatment most common was CAPOX with a median OS of 17 months (p<0.013). The multivariate analysis shows that patients who did not undergo primary surgery had worse disease-specific OS (hazard ratio, CI 2.21.95% [1.15-4.25], p< 0.018) and there was no statistical difference between chemotherapy regimens and treatment line. Conclusions: In young patients with metastatic CRC, Primary tumor surgery and negative perineural invasion are significant factors influencing overall survival. Patients older than 35 years and those who underwent surgery showed better survival. These findings reflect the importance of early colorectal cancer screening and improve the risk assessment.
A Multiresonant Thermally Activated Delayed Fluorescent Dendrimer with Intramolecular Energy Transfer: Application for Efficient Host‐Free Green Solution‐Processed Organic Light‐emitting Diodes
Abstract The development of narrowband emissive, bright, and stable solution‐processed organic light‐emitting diodes (SP‐OLEDs) remains a challenge. Here, a strategy is presented that merges within a single emitter a TADF sensitizer responsible for exciton harvesting and an MR‐TADF motif that provides bright and narrowband emission. This emitter design also shows strong resistance to aggregate formation and aggregation‐cause quenching. It is based on a known MR‐TADF emitter DtBuCzB with a donor‐acceptor TADF moiety consisting of either tert ‐butylcarbazole donors ( tBuCzCO 2 HDCzB ) or second‐generation carbazole‐based donor dendrons ( 2GtBuCzCO 2 HDCzB ) and a benzoate acceptor. The TADF moiety acts as an exciton harvesting antenna and transfers these excitons via Förster resonance energy transfer to the MR‐TADF emissive core. The SP‐OLEDs with 2GtBuCzCO 2 HDCzB and tBuCzCO 2 HDCzB thus show very high maximum external quantum efficiencies (EQE max of 27.9 and 22.0%) and minimal efficiency roll‐off out to 5000 cd m −2 .
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial
PURPOSE The CLL12 trial reassesses the watch-and-wait consensus for early-stage chronic lymphocytic leukemia (CLL) in the context of targeted therapies. METHODS The German CLL Study Group conducted a randomized, double-blind, placebo-controlled phase III trial with 363 patients with asymptomatic, treatment-naïve Binet stage A CLL at increased risk of progression to receive ibrutinib (n = 182) at a daily dose of 420 mg or placebo (n = 181). Additionally, 152 low-risk patients were allocated to the watch-and-wait group. The final analysis included event-free survival, progression-free survival, time to next treatment, overall survival, and safety assessments. RESULTS Ibrutinib significantly delayed progression to symptomatic disease ( P < .001; hazard ratio, 0.276 [95% CI, 0.188 to 0.407]), but no survival benefit was observed with 26 death cases ( P = .562) at a median observation time of 69.3 months. Five-year survival rates were excellent: 93.3% (95% CI, 89.3 to 97.3) in the ibrutinib group, 93.6% (95% CI, 89.5 to 97.7) in the placebo group, and 97.9% (95% CI, 95.6 to 100) in the watch-and-wait cohort. Estimated 10-year survival rates from diagnosis were 86.5% (95% CI, 78.7 to 94.3, placebo), 89.8% (95% CI, 83.3 to 96.3, ibrutinib), and 95.3% (95% CI, 91.1 to 99.4, watch and wait). In the ibrutinib group, one of 12 deaths was CLL-associated, compared with four of 14 fatal cases of CLL progression or Richter transformation in the placebo group. Adverse and serious adverse events occurred in 99.4% and 60% of both treatment groups, respectively. The safety profile indicated increased cardiovascular toxicity in the ibrutinib group. CONCLUSION Ibrutinib treatment in early-stage CLL delayed disease progression compared with placebo. However, with the given observation time and few deaths, no survival benefit was demonstrated. In the era of targeted therapies, watch and wait remains the standard of care irrespective of risk factors.
EVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with pancreatic cancer (PANC) or other mesothelin (MSLN)-expressing solid tumors and human leukocyte antigen (HLA)–A*02 loss of heterozygosity (LOH).
TPS788 Background: MSLN is a desirable candidate for targeted therapy given its limited expression in normal tissues and its overexpression in several malignancies, including PANC, mesothelioma, non-small cell lung, and ovarian cancers (TCGA 2022). MSLN-targeted CAR T and T-cell receptor therapies have shown promising clinical activity; however, on-target, off-tumor toxicity, including fatal events, have occurred (1-3). Autologous logic-gated Tmod CAR T therapies address the challenges of on-target, off-tumor toxicity by combining 2 CARs: activating and blocking receptors. The activator recognizes a tumor-associated antigen present on the surface of both tumor and normal cells; the blocker prevents CAR T activity when it binds HLA-A*02, which is present in normal cells and often lost in tumor cells. Thus, in patients with tumor-associated HLA-A*02 LOH, the blocker prevents on-target, off-tumor toxicity on normal cells due to retained HLA-A*02 expression (4). HLA-A*02 LOH is observed in various solid tumors, including ~20% of PANC (5). Two autologous CAR T therapies are currently under investigation: A2B530, targeting carcinoembryonic antigen, in the EVEREST-1 trial, and A2B694, targeting MSLN, in the EVEREST-2 trial, described herein. A2B694 may provide a therapeutic window to treat patients with PANC and other MSLN-expressing solid tumors exhibiting HLA-A*02 LOH due to its unique discriminatory mechanism. Methods: EVEREST-2 (NCT06051695) is a first-in-human, phase 1/2, open-label, nonrandomized study to evaluate the safety and efficacy of A2B694 for recurrent unresectable, locally advanced, or metastatic cancers with MSLN expression, including PANC. Eligible patients must have exhausted options of potentially curative therapy and have recurrent disease. Enrollment to EVEREST-2 occurs through the prescreening study BASECAMP-1 (NCT04981119), in which patients with tumor-associated HLA-A*02 LOH are identified via next-generation sequencing (Tempus AI, Inc) and leukapheresis product is collected. A2B694 is manufactured from cryopreserved T cells when clinically appropriate for patients. The primary objective of phase 1 is to evaluate the safety and tolerability of A2B694 and identify the recommended phase 2 dose (RP2D). The dose-expansion phase will confirm RP2D and collect biomarker data to further characterize A2B694. Phase 2 will assess the primary endpoint overall response rate per RECIST v1.1 and secondary endpoints progression-free survival and overall survival. The first patient was dosed on April 24, 2024 and dose escalation is ongoing. 1. Beatty, et al. Gastroenterology . 2018. 2. Haas, et al. Mol Ther . 2023. 3. Hong, et al. ESMO 2021. Abstr 9590. 4. Hamburger, et al. Mol Immunol . 2020. 5. Hecht, et al. J Clin Oncol . 2022. Clinical trial information: NCT06051695 .
Impact of inpatient palliative care consultation on end-of-life care among patients with esophageal cancer.
502 Background: Esophageal cancer is an aggressive malignancy with a high global prevalence. Patients often suffer from various debilitating symptoms like dysphagia and cachexia, particularly with more advanced stage disease. Most patients continue to receive aggressive interventions until terminal stages of disease without timely initiation of formal palliative care (PC). We sought to investigate the impact of formal inpatient palliative care consultation on end-of-life (EOL) care among patients with esophageal cancer. Methods: The National Inpatient Sample (NIS) was queried to identify all hospitalizations with esophageal cancer utilizing ICD-10 codes C15.x from 2016 to 2020. Hospitalizations with documented inpatient mortality events were extracted and stratified based on reception of PC consultation (ICD-10 code Z51.5). Demographic and clinical data were analyzed using chi-squared tests and independent sample t-tests. A threshold of p-value less than 0.05 was set to determine statistical significance. Results: A total of 17,745 patients with esophageal cancer were included, of which 10,370 (58.4%) received PC consultation. Patients that received PC consultation at EOL were more likely to have higher comorbidities per CCI. No significant difference between age and sex was observed between the two cohorts. Patients who received PC consultations at EOL had higher rates of Do Not Resuscitate (DNR) code status (78.1% vs 43.2%, p <0.001) and lower rates of aggressive interventions such as chemotherapy (0.9% vs 1.6%, p<.001), blood transfusions (12.3% vs 18%, p<.001), and mechanical ventilation (28.5% vs 41%, p<0.001). No significant difference was observed in the rates of vasopressor use between the two groups (p=0.83). Hospitalizations with PC consultations were associated with significantly lower total hospitalization cost ($97,879 vs $146,128, p<.001). Conclusions: Inpatient PC consultations among patients with esophageal cancer were associated with lower rates of aggressive interventions and higher rates of DNR code status in addition to significantly lower total hospitalization costs. These findings underscore the importance of inpatient PC consultation at the EOL in helping minimize aggressive interpretation and facilitate a greater focus on comfort and quality of life. No PalliativeN=7375 PalliativeN=10370 p-value Age (in years) 67.58 ± 10.9 67.58 ± 10.9 .98 CCI 9.1 ± 3.5 9.4 ± 3.3 <.001 Mean length of stay (days) 8.9 ± 14.9 7.5 ± 11.3 <.001 Total Charges 146128 ± 321830 97879 ± 195868 <.001 DNR 3170 (43.2%) 8100 (78.1%) <.001 Blood transfusion 1320 (18.0%) 1280 (12.3%) <.001 Mechanical ventilation 3015 (41.0%) 2960 (28.5%) <.001 Vasopressor 585 (8.0%) 835 (8.1%) 0.83 Chemotherapy 115 (1.6%) 95 (0.9%) <.001
Predicting the Mechanical Properties of Supramolecular Gels
AbstractThe prediction of gelation is an important target, yet current models do not predict any post‐gel properties. Gels can be formed through the self‐assembly of many molecules, but close analogs often do not form gels. There has been success using a number of computational approaches to understand and predict gelation from molecular structures. However, these approaches focus on whether or not a gel will form, not on the properties of the resulting gels. Critically, it is the properties of the gels that are important for a specific application, not simply whether a gel will be formed. Supramolecular gels are often kinetically trapped, meaning that predicting gel properties is inherently a difficult challenge. Here, the first successful a priori prediction of gel properties for such self‐assembled, supramolecular systems is reported.
Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in <i>BRCA1</i> and <i>BRCA2</i>
PURPOSE It is uncertain whether, and to what extent, hormonal contraceptives increase breast cancer (BC) risk for germline BRCA1 or BRCA2 mutation carriers. METHODS Using pooled observational data from four prospective cohort studies, associations between hormonal contraceptive use and BC risk for unaffected female BRCA1 and BRCA2 mutation carriers were assessed using Cox regression. RESULTS Of 3,882 BRCA1 and 1,509 BRCA2 mutation carriers, 53% and 71%, respectively, had ever used hormonal contraceptives for at least 1 year (median cumulative duration of use, 4.8 and 5.7 years, respectively). Overall, 488 BRCA1 and 191 BRCA2 mutation carriers developed BC during median follow-up of 5.9 and 5.6 years, respectively. Although for BRCA1 mutation carriers, neither current nor past use of hormonal contraceptives for at least 1 year was statistically significantly associated with BC risk (hazard ratio [HR], 1.40 [95% CI, 0.94 to 2.08], P = .10 for current use; 1.16 [0.80 to 1.69], P = .4, 1.40 [0.99 to 1.97], P = .05, and 1.27 [0.98 to 1.63], P = .07 for past use 1-5, 6-10, and >10 years before, respectively), ever use was associated with increased risk (HR, 1.29 [95% CI, 1.04 to 1.60], P = .02). Furthermore, BC risk increased with longer cumulative duration of use, with an estimated proportional increase in risk of 3% (1%-5%, P = .002) for each additional year of use. For BRCA2 mutation carriers, there was no evidence that current or ever use was associated with increased BC risk (HR, 0.70 [95% CI, 0.33 to 1.47], P = .3 and 1.07 [0.73 to 1.57], P = .7, respectively). CONCLUSION Hormonal contraceptives were associated with increased BC risk for BRCA1 mutation carriers, especially if used for longer durations. Decisions about their use in women with BRCA1 mutations should carefully weigh the risks and benefits for each individual.
Association between skeletal muscle morphometrics and overall survival among older adults with gastrointestinal cancers.
808 Background: Older adults with gastrointestinal (GI) cancers face a higher risk of treatment toxicities and adverse survival outcomes. However, the variability in these outcomes remains poorly understood. Age-related changes, including the progressive loss of skeletal muscle and gain in adipose tissue, contribute to this heterogeneity. Recent studies highlight an association between skeletal muscle gauge (SMG) and overall survival (OS) in older cancer patients, but its relevance among those with GI cancers is unclear. Methods: We included adults aged ≥ 60 years with newly diagnosed GI cancers, enrolled in the University of Alabama at Birmingham (UAB) Cancer and Aging Resilience Evaluation (CARE) registry between October 2017 and April 2024. Skeletal muscle index (SMI; skeletal muscle area in m²/height in cm) and skeletal muscle radiodensity (SMD; Hounsfield units) were derived from single-slice computed tomography (CT) staging scans at the third lumbar vertebra (L3) using validated methods. SMG was calculated as the product of SMI and SMD, reported in arbitrary units (AU). Participants were followed until death or the study cutoff date of July 10, 2024. Kaplan-Meier survival analysis was used to estimate OS by SMG status (low: < median; high: ≥ median). Cox proportional hazards models were employed to assess the relationship between SMG and OS, adjusting for age, sex, race/ethnicity, and cancer stage. Results: A total of 568 patients were included in the study, with a median age at diagnosis of 68 years (interquartile range, IQR: 64-74), 55% male, 73% non-Hispanic White, and 43% were diagnosed with Stage IV disease. Colorectal (33%) and pancreatic (27%) cancers were the most common diagnoses. The median SMG was 1,529 AU (IQR: 1,151–1,967). Over a median follow-up of 60 months, 367 patients (64%) died. Median OS was 19 months for those with low SMG and 26 months for those with high SMG (log-rank test, p < .05). After adjustment for confounders, SMG remained independently associated with OS (adjusted Hazard Ratio: 0.678 per IQR increase; 95% CI: 0.57– 0.807; p < .001), indicating that each IQR increase in SMG is associated with a decrease in all-cause mortality risk by 32.2%. Conclusions: Skeletal muscle gauge, an integrated measure of SMI and SMD, is significantly associated with improved survival among older adults with GI cancers. Further research is needed to determine whether SMG has a causal impact on survival in this population.
The prognostic impact of <i>SLFN11</i> gene expression in metastatic colorectal cancer (mCRC).
254 Background: SLFN11 was recently identified as a dominant determinant of response to DNA-damaging anticancer agents. Several studies showed SLFN11 expression led to better sensitivity to topoisomerase inhibitors and PARP inhibitors. However, clinical evidence in mCRC has been lacking. Methods: Two independent cohorts (CALGB/SWOG 80405 trial and a real-world patient [Caris CODEai] cohort) were included in this study. Patients were stratified into SLFN11 -high and -low groups based on the median SLFN11 gene expression levels. Survival outcomes were compared between SLFN11 -high and SLFN11 -low in irinotecan-treated and oxaliplatin-treated patients. Median time was estimated using Kaplan-Meier method and Cox models were used for covariate adjustment. Endpoints of interest were progression-free survival (PFS) and overall survival (OS). Results: In the CALGB/SWOG 80405 trial cohort, 433 patients were included (110 treated with FOLFIRI-based chemotherapy and 323 treated with FOLFOX-based chemotherapy). In patients treated with FOLFIRI-based chemotherapy, SLFN11 -low patients exhibited numerically better PFS (median PFS, 13.4 vs 11.2 months, log-rank p = 0.03, adjusted hazard ratio [HR] = 0.86, 95% confidence interval [CI] 0.55-1.39, p = 0.50) and OS (median OS, 39.6 vs 30.3 months, log-rank p = 0.02, adjusted HR = 0.73, 95% CI 0.46-1.16, p = 0.19) compared to SLFN11 -high patients. In patients treated with FOLFOX-based chemotherapy, SLFN11 -low patients exhibited numerically better PFS (median PFS 11.2 vs 9.8 months, log-rank p = 0.03, adjusted HR = 0.83, 95% CI 0.65-1.05, p = 0.12) and OS (31.1 vs 26.1 months, log-rank p = 0.07, adjusted HR = 0.84, 95% CI 0.65-1.08, p = 0.16) compared to SLFN11 -high patients. No significant interaction was observed between treatment and SLFN11 expression in terms of PFS ( p = 0.69) and OS ( p = 0.44). In the Caris CODEai cohort, a better OS in SLFN11 -low patients than in SLFN11 -high patients was observed in irinotecan-treated patients ( N = 2906) (median OS, 25.5 vs 21.7 months, HR = 0.90, 95% CI 0.82-1.00, p = 0.048). However, no significant difference in OS between SLFN11 -low and SLFN11-high was observed in oxaliplatin-treated patients ( N = 4428) (median OS, 39.5 vs 35.8 months, HR = 0.98, 95% CI 0.90-1.06, p = 0.56). Conclusions: Low SLFN11 expression showed a potential for better prognosis in mCRC patients receiving irinotecan- and oxaliplatin-containing chemotherapies. These findings are not consistently aligned with preclinical data and clinical evidence in other cancer types previously reported. Further investigation is warranted to better understand the biological role and clinical implication of SLFN11 in mCRC.
Imine‐Linked 3D Covalent Organic Framework Membrane Featuring Highly Charged Sub‐1 nm Channels for Exceptional Lithium‐Ion Sieving
AbstractCoupling ion exclusion and interaction screening within sub‐nanoconfinement channels in novel porous material membranes hold great potential to realize highly efficient ion sieving, particularly for high‐performance lithium‐ion extraction. Diverse kinds of advanced membranes have been previously reported to realize this goal but with moderate performance and complex operations gained. Herein, these issues are circumvented by preparing the consecutive and intact imine‐linked three‐dimensional covalent organic framework (i.e., COF‐300) membranes via a simple solvothermal approach and employing the intrinsically interconnected sub‐1 nm one‐dimensional channels for exceptional lithium‐ion sieving. The synthesized membranes with highly charged angstrom scale channels of ≈0.78 nm achieve an excellent Li+ permeance (0.123 mol m−2 h−1) with an ultrahigh Li+/Mg2+ of 36 in the binary system. The experimental measurement and theoretical calculation reveal that a channel size right exactly between Li+ and Mg2+ enables restricted Mg2+ penetration. Meanwhile, the ion affinity interaction screening with imine groups further strengthens the fast Li+ permeability but severely suppresses the Mg2+ passage. In particular, the synthesized three‐dimensional covalent organic framwork membranes also have a remarkable separation performance during a long‐term operation test without sacrificing trade‐off, demonstrating chemistry stability and mechanical integrity under the high‐salinity aqueous environment.
A systematic review of the impact of artificial intelligence in pancreatic cancer detection.
685 Background: Pancreatic cancer is the fourth leading cause of cancer deaths in the United States, and early detection remains a significant challenge. Screening the general population is not feasible, but the rise of artificial intelligence (AI) has introduced new possibilities for improving early diagnosis and patient outcomes. Methods: A systematic literature search was conducted using PubMed, Google Scholar, and MEDLINE using MeSH terms Artificial intelligence or AI, and diagnosis and pancreatic carcinoma or pancreatic adenocarcinoma. Prisma guidelines were adhered to, and a total of 19 studies resulted, 6 of them were retrospective studies, 4 of them were literature reviews, and 4 of them were randomized trials. The rest were duplicates. The inclusion criteria for this study is AI being used in the diagnosis, only in pancreatic cancer, within the last 5 years, only in English, and only retrospective studies were included. Results: One study used Digital Imaging Processing (DIP) for analyzing Endoscopic ultrasound (EUS) images from 153 pancreatic cancer patients, yielding a sensitivity of 97.98% and a specificity of 94.32%. Two studies explored Computer Aided Diagnosis (CAD) models applied to PET/CT and EUS images, achieving a sensitivity of 95.23% and specificity of 97.51% in PET/CT scans and 83.3% and 93.3% in EUS images, respectively. Another study used a Faster R-CNN model to analyze CT images from 338 pancreatic cancer patients showed high diagnostic accuracy in much less time. Additionally, two studies utilized Natural Language Processing (NLP) for identifying family histories of pancreatic cancer and detecting pancreatic cysts, with the latter achieving sensitivity and specificity rates of 99.9% and 98.8%. Conclusions: The current strategies for early diagnosis of pancreatic cancer focus on serum biomarkers and EUS-guided Fine Needle Aspiration (EUS-FNA) and sensitivity varies but depends on the physician's expertise. AI is showing promise in improving pancreatic cancer diagnosis by enhancing early detection and accuracy. Techniques like deep learning, NLP-based models, Faster R-CNN, and CAD systems analyze medical data and images more effectively than manual methods. AI holds the potential to shape the future of pancreatic cancer diagnosis and improve patient outcomes.